The Sodium/Bile Acid Cotransporter pipeline drugs market research report outlays comprehensive information on the Sodium/Bile Acid Cotransporter targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sodium/Bile Acid Cotransporter pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Gastrointestinal, Metabolic Disorders, and Undisclosed which include the indications Hepatitis B, Hepatitis D, Primary Sclerosing Cholangitis, Cholestasis, Unspecified Metabolic Disorders, and Unspecified. It also reviews key players involved in Sodium/Bile Acid Cotransporter targeted therapeutics development with respective active and dormant or discontinued products.
The Sodium/Bile Acid Cotransporter pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, and Preclinical stages are 1, 2, 2, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Sodium/Bile Acid Cotransporter overview
Sodium/Bile Acid Cotransporter is a protein and is encoded by the SLC10A1 (solute carrier family 10 member 1) gene. This is also known as Na+-taurocholate co-transporting polypeptide (NTCP) and is expressed in the basolateral membranes of hepatocytes. This protein belongs to sodium/bile acid cotransporter family, which are integral membrane glycoproteins and participate in the enterohepatic circulation of bile acids. Sodium/Bile Acid Cotransporter is important for cholesterol homeostasis.
For a complete picture of Sodium/Bile Acid Cotransporter’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
